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and beneﬁcial outcomes primarily come from studying ﬁlling/con-
sumption behaviors after therapy initiation. Few studies have focused
on what happens before initiation, the point from prescribing to
dispensing of an initial prescription. Objective: Our objective was to
provide guidance and encourage high-quality research on the rela-
tionship between beneﬁcial outcomes and initial medication adher-
ence (IMA), the rate initially prescribed medication is dispensed.
Methods: Using generic adherence terms, an international research
panel identiﬁed IMA publications from 1966 to 2014. Their data
sources were classiﬁed as to whether the primary source reﬂected
the perspective of a prescriber, patient, or pharmacist or a combined
perspective. Terminology and methodological differences were docu-
mented among core (essential elements of presented and unpre-
sented prescribing events and claimed and unclaimed dispensing
events regardless of setting), supplemental (reﬁned for accuracy), and
contextual (setting-speciﬁc) design parameters. Recommendations were
made to encourage and guide future research. Results: The 45 IMAee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.02.015
tchins@caremark.com.
ndence to: David S. Hutchins, CVS Caremark, 9501studies identiﬁed used multiple terms for IMA and operationalized
measurements differently. Primary data sources reﬂecting a prescriber’s
and pharmacist’s perspective potentially misclassiﬁed core parameters
more often with shorter/nonexistent pre- and postperiods (1–14 days)
than did a combined perspective. Only a few studies addressed suppl-
emental issues, and minimal contextual information was provided.
Conclusions: General recommendations are to use IMA as the standard
nomenclature, rigorously identify all data sources, and delineate all
design parameters. Speciﬁc methodological recommendations include
providing convincing evidence that initial prescribing and dispensing
events are identiﬁed, supplemental parameters incorporating perspec-
tive and substitution biases are addressed, and contextual parameters
are included.
Keywords: good research methodology, initial compliance, initial
medication adherence, medication adherence.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Medications are the most common treatment regimen used in
ambulatory health care [1]. Yet, adhering to prescribed medications
is a major issue affecting health care because nonadherence has
been associated with worsening clinical symptoms and disease pro-
gression [2–10]. Furthermore, medication nonadherence has been
linked to increased health care visits, services, and costs [11–15].
Studies linking nonadherence to these unfavorable outcomes have
used various operational deﬁnitions for adherence—each with its
own nomenclature (e.g., persistence), several representing similar if
not exact components of medication adherence [2,13,16].In two studies, taxonomic language has been developed to
help researchers and clinicians understand subtle, yet power-
ful, differences among the processes inherent in adhering to
prescribed medication regimens [16,17]. Although both taxon-
omies include an initiation point, which signiﬁes the start of
the medication adherence continuum, most of their focus is on
what happens during implementation and discontinuation of
medication therapy. We collectively refer to implementation
and discontinuation of medication therapy as postinitia-
tion medication adherence (PIMA) processes. The patient’s
intention to initiate the medication regimen is omitted [17] or
given only limited attention [16]. Our focus is on this vitalociety for Pharmacoeconomics and Outcomes Research (ISPOR).
E. Shea Boulevard, MC 020, Scottsdale, AZ 85260.
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tion adherence (IMA).
IMA is simply deﬁned as the patient obtaining, for the ﬁrst
time, a new prescription medication. This is operationalized by
two distinct events: a provider prescribing a medication for the
ﬁrst time, that is, a prescribing event, and a pharmacist dispens-
ing this initial prescription, that is, a dispensing event. An
initiation failure occurs whenever an initial prescription is not
presented to a pharmacist or a presented prescription is not
dispensed by a pharmacist. When this failure occurs, IMA is not
achieved.
Although conceptually simple, IMA lacks the depth of explo-
ration attributed to PIMA and suffers from a similar proliferation
of terms. These issues are reﬂected in our recent systematic
review in which only 24 of 865 selected publications examined
IMA risk factors [18]. Disparity between the volume of published
IMA and PIMA research may be due to the availability of data for
measuring each in a cost-effective way. Information needed for
measuring many aspects of PIMA is captured and readily avail-
able on a large scale in most US retrospective claim databases
[19]. In contrast, the prescribing and dispensing events needed to
measure IMA are seldom captured together, lack the necessary
linkages, or are insufﬁcient in quantity. Until recently, initial
prescriptions were almost always handwritten and given to
patients for ﬁlling at a pharmacy of their choice, though some
health care systems do have pharmacy restrictions on that
choice. In this environment, documenting ﬁlling behaviors has
historically involved surveys, phone calls, data extraction, or
other manually intensive techniques. The few health care sys-
tems that capture the information electronically have population
sizes, privacy issues, and organizational resources that limit the
production of disease-speciﬁc IMA rates. These are just some of
the issues that contribute to the dearth in IMA research. Yet, IMA
is the ﬁrst step to realizing adherence beneﬁts for both acute and
chronic conditions. As such, increasing the body of IMA literature
would provide baseline rates to support measuring the impact of
interventions and additional insights into factors associated with
initiation failures. Identiﬁcation of this information can help to
develop targeted interventions and lead to improved patient
outcomes.
Building upon our past work on IMA [18], the purpose of this
article was to assess the extent and means by which IMA has
been operationally deﬁned and provide guidance for future
research in this area [16]. This article is not intended to be an
exhaustive review with a meta-analysis of IMA research. Instead,
the focus is on operational design to foster more coherent and
standardized approaches to conducting, analyzing, and interpret-
ing IMA research. As the body of IMA research grows, we expect
that it will provide additional insights into achieving clinical,
utilization, and cost beneﬁts more commonly associated with
PIMA [2].Methods
An international panel of researchers with considerable expertise
in medication adherence and research formed a leadership team
on IMA as part of ISPOR’s Medication Adherence Good Research
Practices Working Group in July 2009. The leadership team
divided into two groups to identify initial adherence rates and
factors that inﬂuenced whether patients would ﬁll their initial
prescription. Finding insufﬁcient IMA research to produce
disease-speciﬁc rates with conﬁdence, the two groups rejoi-
ned to publish ﬁndings on behavioral factors inﬂuencing the
IMA goal [18]. Following this publication, we updated our earlier
search and found that circumstances had not changed enough
to identify initial condition-speciﬁc adherence rates. In short,research was still fragmented, terminology and operational
deﬁnitions were inconsistent, and methodologies were unclear.
This ﬁnding is similar to that obtained in other recently pub-
lished reviews [17]. To foster a proliferation of high-quality
studies supporting the production of IMA condition-speciﬁc rates
and solidifying the relationship between IMA and beneﬁcial
outcomes, the team decided to provide guidance for IMA
research.
The key terms included initial, primary, ﬁrst-ﬁll, and early
with adherence and compliance to search Medline (PubMed and
Ovid), the Cochrane Library, PsycInfo, Scopus, Web of Science,
Embase, and CINAHL databases [18]. The search extended from
inception of the database to January 2014. We considered studies
that measured IMA but did not have a link to behavioral factors.
Selected studies had to conform to our deﬁnition of initial
adherence, include primary data analysis, and have more than
10 patients. Articles presenting only conceptual or theoretical
work or those dealing with adherence during the early treatment
course or longitudinal persistence rather than the very ﬁrst
prescription were excluded. Two independent reviewers applied
these criteria to review the titles, key words, and abstracts to
determine which full-text publications would be reviewed and
ultimately whether a study would be included. The reviewers
documented information on study location, sample size, periods,
and reference frame, which provide context for presenting and
interpreting study differences.
The IMA Process
The study reference frames are categorized into whether the
primary data source reﬂected a prescriber, patient, pharmacist, or
combined approach to the IMA process. The IMA process begins
with a prescriber and patient interaction in an emergency room/
department, hospital, or other clinic setting (step 1) that results in
a prescribing event (step 2)—the ﬁrst of the two key events
needed for an IMA measurement (Fig. 1). When a prescribing
event occurs, data collected from the perspective of either a
prescriber or a patient will capture it, whereas data collected from
the perspective of a pharmacist will not. To qualify as IMA,
however, the prescribing event must relate to a patient’s ﬁrst
prescription within a therapeutic class (step 4). Otherwise, the
dispensing event becomes part of a PIMA metric (step 5). Data
from either the patient or the prescriber should be able to
determine whether the prescribing event is an initial event.
The pharmacist becomes aware of prescribing events only
when these events are communicated to the pharmacist for
ﬁlling (step 6). Therefore, the pharmacist does not know how
many prescribing events have occurred, only how many have
been communicated. However, once the pharmacist receives the
prescription (step 7) and ﬁlls it (step 8), the pharmacist must
dispense the prescription to the patient (step 9). The dispensing
event is the second key event needed for measuring IMA (step
10). With dispensing the medication to the patient, both the
pharmacist and the patient know that the IMA is achieved, but
the prescriber does not. If a pharmacist does not dispense a ﬁlled
prescription, the prescription becomes abandoned to the phar-
macist and is restocked (step 11). If an abandoned prescription is
not transferred to another pharmacist (step 12) and subsequently
dispensed, the patient will be initially nonadherent (step 13).
Either the pharmacist or the prescriber may transfer the pre-
scription from one pharmacy to another, but neither may know
that the prescription has been dispensed. Thus, data from only a
patient’s perspective and the dispensing pharmacy can verify
whether a dispensing event occurs.
For the purposes of this review, study design parameters were
divided into core, supplemental, and contextual parameters. Core
parameters are those that must be provided to calculate a valid
Fig. 1 – The Initial Medication Adherence Process and its Key
Perspectives.
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accuracy of the measurement, and contextual parameters are those
factors that may inﬂuence the measurement. General and design
parameter recommendations are made for improving the quan-
tity and quality of IMA measurements. In addition, universal
recommendations are made to improve documentation of IMA
research.Results
Characteristics of the 45 published IMA studies selected for
inclusion are presented in Table 1. A total of 29 studies
came from within the United States [8,9,12,19–45] and 16 from
outside the United States [4,5,46–59]. The IMA publications were
classiﬁed by primary data source into the following perspec-
tives: 12, prescriber [23,26,32,33,38,46,47,49,51,52,57,58]; 3, patient
[12,41,56]; 7, pharmacist [24,27,29,30,37,53,54]; and 23, combined
[4,5,8,9,19–22,25,31,34–36,39,40,42,44,45,48,50,55,59,60].
The time frame used to identify prescribing and dispensing
events for each study is also given in Table 1. The time frame
consists of a preperiod and a follow-up period. The preperiod is
the length of time before a prescribing event used to determine
whether it was an initial prescribing event. The follow-up period is
the length of time after the prescribing event researchers looked
for a dispensing event. The inﬂuence that each perspective has
on these time-frame components is presented in the Core
Parameter section. Other differences among the studies and
some techniques used to overcome inherent data limitations
associated with using data captured from the perspectives of the
primary data source are presented in Supplemental and Con-
textual Parameter sections.Core Parameters
In general, studies measuring IMA provided details on the
relevant medications, the means for capturing prescribing and
dispensing event information, and the time frames used for the
preperiods and the follow-up periods. The medication list iden-
tiﬁes what dispensing and prescribing events are being tracked,
whereas the preperiod is used to determine when a patient
initiates pharmacotherapy for a new class and the length of the
postperiod that is used to detect dispensing events. These details
about the prescribing and dispensing events are the core param-
eters. Ideally, these details provide the information to determine
precisely whether and when these key events occurred for
numerous patients.
Although it may be impossible to have all the prescribing and
dispensing information, there were differences among the stud-
ies related to their primary data source perspectives. In general,
studies with data from a clinical (i.e., prescriber’s or pharmacist’s)
perspective had relatively shorter time frames for detecting the
prescribing and dispensing events and used fewer comprehen-
sive information sources than did those that considered claims
and other electronically captured sources (see Table 1). In
addition to having nonexistent preperiods, many of these studies
had relatively short follow-up periods ranging from 1 to 21 days
[26,30,32,38,46,51,52,54,57]. Five had 1-month follow-up periods
[23,29,33,47,49], four had 90- to 180-day follow-up periods
[27,37,53,58], and two had variable follow-up periods up to a year
[3,58]. Furthermore, although the prescriber generally had infor-
mation on the prescribing event and the pharmacist generally
had information on the dispensing event, only the prescriber’s
perspective studies incorporated study design parameters to
capture the missing event information with manual direct
patient or pharmacy contact. Thus, on the basis of evidence from
these studies, the pharmacist was less likely to account for
missed prescribing events and unpresented/communicated pre-
scriptions compared with the prescriber accounting for missed
dispensing events. In addition, prescriber or pharmacist perspec-
tives without a preperiod would likely be unable to distinguish
between medication initiation and continuation. This lack of a
preperiod would mean that it is difﬁcult to separate IMA meas-
urements from PIMA measurements.
Studies involving data on both key events from a combined
perspective or a patient’s perspective had mixed results. Almost
all studies that used data sources from a combined perspective
had at least a 6-month preperiod, with some having a year or
more [4,5,8,9,19–22,25,28,34–36,39,40,44,45,50,55,60]. Similarly, most
had at least a 28-day follow-up period, with several having 12
months or more. Prescribing event information was generally
captured electronically through an electronic medical record or a
system devoted exclusively to electronic prescribing in studies
using a combined perspective. They also captured whether a
medication had been ﬁlled through electronically maintained
dispensing records within the pharmacies or by pharmacy beneﬁt
managers. In contrast, the length of the preperiods and follow-up
periods was less deﬁned in the three studies that approached the
question from a patient’s perspective. All three studies relied on a
single question within a larger survey about whether the
respondent had failed to ﬁll a prescription in the last 3 months
[56] or last 12 months [12,41]. The ambiguity of the question
relating to the preperiods and follow-up periods likely led to
variable period lengths, and in these studies there was no
information on whether it was an initial prescription within a
therapeutic class.
Supplemental Parameters
Supplemental design parameters provide details on how biases
associated with perspective, substitution, and censoring—each
Table 1 – Key IMA characteristics of publications (n ¼ 40).
Perspective* Country Sample size† Study
period‡
Prescribing event
periods§
Reference no. Author (year) Pre Follow-up
Prescriber
[46] Arslan and Semin (2006) Turkey 280 Patients Feb 2003 to
Jun 2003
0 5
[47] Beardon et al. (1993) Scotland 4,854 Patients Jan 1989 to
Apr 1989
0 30
[23] Fernando et al. (2012) United States 224 Patients Jun 2010 to
Dec 2010
0 7–31
[49] Freeman and Guly
(1985)
England 226 Prescriptions Feb 1983 0 0–30
[26] Ginde et al. (2003) United States 31 Patients Nov 2001 to
Jun 2002
0 5–7
[51] Jones and Britten (1998) England 935 Patients Jan 1996 0 21
[52] Matsui et al. (2000) Canada 1,014 Patients Sep 1996 Jan
1997 to Mar
1997
0 2
[32] Rosman et al. (2012) United States 111 Families Jan 2009 to
Apr 2010
0 3
[33] Saks et al. (2012) United States 160 Patients Jan 2009 to
Mar 2010
1 30
[38] Suffoletto et al. (2012) United States 200 Patients Jun 2011 to
Sep 2011
365 1
[57] Watts et al. (1997) Australia 359 Prescriptions 3 mo in 1993 0 21
[58] Wright et al. (2003) Australia 65 Prescriptions Apr 2000 to
Jul 2000
NA 0–90
Patient
[12] Esposito et al. (2008) United States 1,214 Patients Jun 2003 to
May 2004
0 1–365
[56] Wamala et al. (2007) Sweden 31,895 Patients Mar 2004 to
Jun 2004,
Mar 2005 to
Jun 2005
NA 0–90
[41] Wroth and Pathman
(2006)
United States 3,926 Patients Nov 2002 to
Jul 2003
NA 0–365
Pharmacist
[27] Gleason et al. (2009) United States 10,104 Patients Jul 2006 to
Dec 2008
90 90
[24] Fincham and
Wertheimer (1986)
United States 32 Patients 4-mo period 0 14
[30] McCaffrey et al. (1995) United States 522 Pharmacies 8 wk 0 7
[29] McCaffrey et al. (1998) United States 128 Pharmacies 12 wk 0 30
[53] Menckeberg et al. (2008) The Netherlands 667 Patients 6 y 730 180
[54] Skutnik and Katsanis
(1997)
Quebec 254 Prescriptions 4-wk period 0 14
[37] Streeter et al. (2011) United States 10,508 Patients May 2007 to
Jun 2009
120 90
Combined
[20] Berger et al. (2009) United States 2,023 Patients Jan 2002 to
Dec 2006
180 30
[21] Cheetham et al. (2013) United States 19,826 Patients Dec 2009 to
May 2010
365 90
[22] Derose et al. (2013) United States 2,606 Patients Apr 2010 to
Jun 2010
365 7–60
[48] Ekedahl and Mansson
(2004)
Sweden 91,704 Prescriptions Mar 2000 to
Sep 2000
0 120–210
[25] Fischer et al. (2010) United States 75,589 Patients Apr 2004 to
Mar 2005
180–365 0–365
[60] Fischer et al. (2011) United States 280,081 Patients Jul 2007 to
Dec 2009
180 180
continued on next page
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Table 1 – continued
Perspective* Country Sample size† Study
period‡
Prescribing event
periods§
Reference no. Author (year) Pre Follow-up
[50] Hansen et al. (2004) Denmark 4,860 Patients Jan 1998 to
Jun 1999
1,825 180
[4] Jackevicius et al. (2008) Canada 4,591 Patients 2008 120 120
[42] Karter et al. (2009) United States 27,329 Patients Jan 2004 to
Jun 2008
730 30
[5] Ko et al. (2009) Canada 11,344 Patients Dec 2003 to
Mar 2007
90 365
[44] Liberman et al. (2010) United States 23,176 Prescriptions Jan 2005 to
Dec 2006
180 60
[19] Raebel et al. (2011) United States 15,147 Patients Jan 2007 to
Jul 2008
365 30
[31] Raebel et al. (2011) United States 16,173 Patients Jan 2007 to
Jul 2008
365 30
[9] Shah et al. (2009) United States 3,240 Patients Jan 2002 to
Dec 2006
365 30
[8] Shah et al. (2009) United States 1,132 Patients Jan 2002 to
Dec 2006
365 30
[34] Shin et al. (2012) United States 569,095 Prescriptions Dec 2009 to
Feb 2010
365 14
[35] Shrank et al. (2010) United States 5,249,380 Patients Jul 2008 to
Dec 2008
180 90
[36] Solomon et al. (2009) United States 17,183 Patients 1997– 2002 365 0–1825
[55] Storm et al. (2008) Denmark 322 Patients 2006 180 28
[39] Trinacty et al. (2009) United States 1,906 Patients 1992–2001 365 365
[40] Williams et al. (2007) United States 1,064 Patients Feb 2005 to
May 2006
365 90
[59] van Geffen et al. (2009) The Netherlands 965 Patients 2001 180 30
[45] Yood et al. (2008) United States 236 Patients At least 2.5 y 180 90
IMA, initial medication adherence; NA, not applicable/available.
* The data source perspective as reﬂected in the IMA process.
† The number of patients was reported unless it was not given; otherwise, prescriptions or pharmacies.
‡ Study period encompasses the look-back, dispensing event identiﬁcation, and follow-up periods.
§ Some lengths were interpreted from provided statements such as from the prescribing event through the end of the study period.
Months were interpreted as 30 days and a year as 365 days.
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be addressed. Perspective bias occurs if prescribing or dispensing
events are missed because data are limited to one perspective.
For example, using data from only a pharmacist’s perspective
misses prescribing events, using data from only a prescriber’s
perspective misses dispensing events, and relying on a single
administrative data source misses dispensing events if a patient
opts out of using the covered beneﬁt for another beneﬁt source
or for cash. Substitution bias occurs whenever the patient
receives an alternative to the initially prescribed medication.
Such substitutions may occur for various reasons, including
insurance purposes, to minimize adverse drug reactions that
might have been observed from a sample, in response to
symptom improvements or negative test results, when an
equivalent substitute is more readily available or less expensive,
or when a newer medication with fewer adverse effects or
with better therapeutic beneﬁts is released. Any of these sub-
stitutions qualify as a dispensing event for the initial medica-
tion and are the primary reasons that therapeutic classes rather
than individual medications need to be a focus of IMA measure-
ments. Finally, censoring bias occurs when events such as
hospitalizations and death intervene to eliminate the possibility
of capturing a dispensing event within the time frame of theresearch. The biases that a study addresses depend on the drugs
and patient population being studied. For instance, censoring
events such as rehospitalization and death may be more likely
among patients discharged from the hospital after myocardial
infarction. Likewise, patients prescribed therapies from certain
medication classes, such as nonsteroidal anti-inﬂammatory
drugs, may substitute prescribed medications for over-the-
counter medicines without compromising medication intent or
outcome. Finally, areas with a relatively transient population,
such as a tourist location, may bias an IMA analysis if the
patient returns home before ﬁlling the prescription.
A few studies have included supplemental parameters in their
research design that addressed one or more of these three types
of biases. Perspective bias has been addressed in several ways,
including describing limits to the health care delivery system
[48,50,57], determining from electronic health records whether
prescriptions were transferred out of network [19,47], discovering
erroneous transmittals to a pharmacy, and misidentifying PIMA
as IMA [48]. Several more studies have applied criteria—such as
system use and beneﬁt eligibility—to ensure that dispensing
event information would be captured [8,20–22,34]. Through sur-
veys, studies have addressed substitution biases resulting from
changing the prescribed medication before ﬁlling the original
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instead of the prescribed medication to reduce cost, and identi-
fying instructions directing the patient to take the medication
only if the symptoms persisted [51,53]. Others have addressed
substitution bias by using a class coding system such as the
Generic Product Indicator or the Anatomical Therapeutic Chem-
ical classiﬁcation rather than just the names of medications with
the same active ingredients as those ordered in the original
prescription [22,34,44,48,50,53,57,60,61]. Some researchers have
even applied clinical criteria to ensure that medication substi-
tutes were for the correct condition or diagnosis when multiple
therapeutic possibilities existed for a medication. Furthermore,
therapy changes made at the pharmacy could erroneously
classify patients as nonadherent when they were actually
switched to another class [8]. Death and emigration were two
censoring events that Hansen et al. [50] used to exclude pre-
scriptions from IMA calculations though the means used to
identify the events were not presented. In other research,
follow-up surveys/calls have been used to identify censoring
events such as death and hospitalization [47,48].
Contextual Parameters
Although not central to the actual measurement of IMA, con-
textual parameters provide insight into the observed IMA rates
and assist with understanding how the ﬁndings may be gener-
alized across patient groups and health care environments.
Contextual parameters comprise patient and nonpatient charac-
teristics. Patient characteristics include demographic and behav-
ioral factors such as age, sex, race, health beliefs, income,
comorbidities, support network, and other patient-speciﬁc char-
acteristics that might inﬂuence ﬁlling a prescription. Nonpatient
characteristics include characteristics such as the health system,
covered beneﬁts, provider and pharmacy characteristics, and
other factors that may inﬂuence the prescribing or dispensing
events.
Research documenting a relationship between contextual
parameters and PIMA is more prevalent than with IMA. Even
some studies that purported to explore the relationships between
IMA and contextual parameters actually studied PIMA instead,
examining factors following a ﬁrst prescription [62–64]. For
those articles that examined IMA, associated factors included
various patient and nonpatient factors, including demographic
characteristics and socioeconomic status characteristics
[35,56,59], speciﬁc medication or drug class [31,43], illness severity
or medical comorbidities [5], and drug cost or pharmacy co-
payments [42,43]. In addition, health beliefs, concerns for adverse
effects, and even receipt of medication counseling inﬂuenced the
likelihood of IMA [4,45,53]. It should be noted that studies that
expanded their goals to cover early implementation or persis-
tence over 1 to 2 years revealed similar risk factors for poor
adherence. When examining the role of patient characteristics or
other behaviors associated with IMA, however, studies are
needed to clearly document this goal through appropriate key
words, abstract details, and Methods sections to identify their
objectives to the reader. This clarity distinguishes studies exam-
ining discontinuation or early implementation adherence
from IMA.Discussion/Recommendations for Good Practices
The ISPOR Medication Adherence Good Research Practices Work-
ing Group has developed a set of recommendations to guide
future investigators into producing high-quality IMA research.
Summarized in Table 2, these recommendations promote a
standard of excellence for examining IMA. The recommendationsshould help researchers, health system practitioners, patients,
and policymakers take advantage of this research and the
implications arising from an increasingly important body
of work.
General Recommendations
First among the general recommendations is to consistently use
IMA when presenting research in this area. The IMA term was
selected because it1. reﬂects the position between prescribing and dispensing as
the initial step along the medication adherence continuum
[16].2. ﬁts well with PIMA as a means for describing the medication
adherence continuum parts.3. avoids some issues associated with the use of other terms.
a. “Abandoned” has been used almost exclusively from a
pharmacist’s perspective to refer to prescriptions that were
ﬁlled but not dispensed within their network. These
studies miss dispensing events occurring outside their
network and unpresented prescribing events. In addition,
these studies lack information on where a prescription
belongs along the medication adherence continuum.
b. “Primary” has most often been used in prescriber’s per-
spective studies to reﬂect the ﬁlling of any new prescrip-
tion regardless of where it occurs along the medication
adherence continuum. Thus, it encompasses initial dis-
pensing events associated with IMA and renewal dispens-
ing events that often occur at least once a year. In
Pharmacy Quality Alliance’s primary nonadherence met-
ric, the term “primary” is limited to a pharmacist’s per-
spective (for pharmacy or pharmacy networks only),
e-prescribed chronic medications, and a 30-day follow-up
period that can detract from broader application [65]. The
term primary also seems to imply that related terms, for
example, secondary or tertiary, would be appropriate
though they were not used in any medication adherence
studies and do not appear as points along the medication
adherence continuum.
c. “Acceptance” (and similar terms) has connotations that
imply intentional patient motives for adherence that may
not exist. For instance, patients may accept the need for
the prescribed medication but lack the means to acquire it.
d. “Nonchronic,” an extension of referring to PIMA as chronic
therapy, may be misconstrued to associate IMA only with
acute or chronic medications though IMA applies to both.
e. “Early,” “ﬁrst,” and other terms have been used for several
PIMA metrics (e.g., early discontinuation, ﬁrst-ﬁll-drop off),
contributing to the proliferation of terms and existing
confusion.By consistently using the IMA term throughout indexed key
terms, abstracts, and within published articles, the identiﬁca-
tion of relevant research through search engine inquiries will
become more systematized. This systemization will allow better
access to currently available information and reduce confusion
and misunderstandings that impede comparisons across similar
research.
The second recommendation requires specifying whether a
patient, provider, pharmacy, or combined perspective is being
taken to conduct the research. Each research perspective pos-
sesses its own advantages and disadvantages and therefore
provides context as to the possible pitfalls in estimating IMA
rates. These inherent pitfalls help determine which design
parameters are most important to incorporate. The third recom-
mendation is to delineate the speciﬁc elements or domains that
Table 2 – Recommendations for IMA research methodology.
Recommendations Additional information/examples
General
1 Use the term initial medication adherence. Initial medication adherence describes the point along a treatment
continuum being measured and should be used in titles, abstracts,
key words, and throughout the manuscript.
2 State/deﬁne the speciﬁc research perspective taken. Stating the data source perspectives—whether it be from the
perspective of a patient, prescriber, or pharmacy, or a combined
perspective—provides context for appropriately interpreting,
ﬁnding, and identifying likely limitations to be addressed.
3 Delineate the core, supplemental, and contextual
parameters that will be covered.
Core prescribing and dispensing event information must be provided
or IMA cannot be measured.
Supplemental parameters speciﬁc to the patient group and condition/
symptoms being treated provide context for determining relevance,
validity, and generalizability.
Delineating the contextual factors enhances the salience of the
research and improves the precision of the measurement.
Core
4 Provide sufﬁcient details on the prescribing event and the
procedures for determining a new therapeutic class/initial
Rx.
Ideally, prescribing event details include the following:
 Scope of the data captured including data sources (e.g., provider
charts and notes, patient surveys, medical records, and electronic
medical or prescribing databases) and health care system within
which patients are treated (e.g., closed, open but eligibility
information veriﬁed).
 Disease treated and the medications included in the therapeutic class
covering possible adjunct or true initial therapy.
 Actions taken to exclude renewed or other PIMA prescriptions,
including length of time used to identify initiators.
 Instructions the patient may have received that might impact ﬁlling
behavior (e.g., PRN, or if symptoms persist).
5 Specify the dispensing event time frame for the dispensing
event and justify selection.
Dispensing event details include the scope of the data captured, the
ﬁxed length of time after the prescribing event that a dispensing
event was considered, how the length of time was determined, and
any sensitivity analyses performed that support that the selected
follow-up period for the therapeutic classes was long enough to not
miss true dispensing events for the prescribing event, but short
enough to not include other prescribing events.
Supplemental
6 Address perspective bias by ensuring the
comprehensiveness of information sources.
Address the limitation of the perspective taken, such as prescriptions
being redeemed out of network, so that IMA rates will not be
artiﬁcially low because of missed dispensing events.
7 Address substitution bias regardless of the source. Address the bias that occurs from narrowly deﬁning what constitutes
a dispensing event by accounting for possible substitutions if
multiple medications can be used to treat the same condition;
beneﬁt coverage favors lower costing alternatives including over-
the-counter drugs.
Contextual
8 Include patient characteristics information. Patient characteristics such as treatment beliefs, insurance coverage,
access barriers, disease severity, comorbidities, and support
network provide additional context for interpreting and applying
results to more relevant populations to the audience, particularly if
the appropriate statistical test provide information on the relative
association between individual characteristics and IMA.
9 Include nonpatient characteristics. Nonpatient characteristics such as the health system (e.g., HMO or
private family medicine clinic), provider, formularies, advocacy and
other support groups, medications payment policies, connection
among prescribing and dispensing units, and the pharmacy (e.g.,
onsite vs. community, paper vs. electronic prescription, HMO, and
private family medicine clinic) can impact health policy,
dissemination, generalizability, or quality improvement efforts
made more salient if the associations have statistical signiﬁcance.
Terms in bold highlight the key concepts that categorize the recommendations presented in the additional information/examples column and
the term initial medication adherence was italicized to emphasize the importance of using the term. HMO, health maintenance organization;
IMA, initial medication adherence; PIMA, postinitiation medication adherence; PRN, pro re nata (when necessary).
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study design parameters. These parameters provide vital infor-
mation to the intended audiences by providing study context,
details of the methodological approach, and information on the
generalizability. All this information is useful for guiding inter-
pretations and informing quality improvement efforts.
Core Recommendations
The core recommendations provide details on prescribing and
dispensing events and on how the therapy was determined to be
an initiation, including but not limited to1. describing study design parameters that ensure
a. all the prescribing and dispensing events are being
captured.
b. pre-prescribing and postprescribing event periods are long
enough to account for common number of days supplied,
possible substitutions, pharmacokinetics, pharmacody-
namics, exhaustion of potential samples, return to stock,
and similar issues related to the medication and data
sources. For acute conditions, pre- and postprescribing
periods may be as short as 7 to 10 days. For chronic
conditions, pre-prescribing periods should be at least 6
months to a year and postprescribing, 15 to 30 days.
c. the same length of time is being used to determine
whether a prescription in a prescribing event represents
an initiation.2. focusing on multiple medications rather than a single medi-
cation that can be used to treat the conditions/symptoms of
the originally prescribed medication to ensure appropriate
substitutions are considered.3. explaining how the sample size was determined to be large
enough to provide a valid measure.
Providing these details conveys information on the validity and
reliability of the IMA calculations. At a minimum, these calcu-
lations should include an adherence rate (i.e., number of dis-
pensing events divided by number of prescribing events), though
calculating a time to initiation and metrics for multiple groups
offers valuable insights and may have an association with
clinical, ﬁnancial, and utilization beneﬁts. More research is
needed to establish these associations.
Among the reviewed studies, those from a combined perspec-
tive are the only ones that consistently provided these core
parameter details. Some of the other studies, however, do
describe data sources they used to capture missing prescribing
and dispensing event information. These data sources include
medical charts, patient surveys, pharmacy records, claims data-
bases, electronic prescribing databases, mobile phone “apps,” and
other records. From our experiences, searching through paper-
based records is time consuming and error prone, leading to
misidentifying PIMA as IMA. Similarly, surveys can provide
valuable information but they may be imprecise and are subject
to patient recollection. Whether the effort and associated
expenses to collect enough prescribing and dispensing events
from these sources is pursued may depend on the value those
sources can provide for improving adherence. For instance,
mobile phone applications might open direct communication
lines between patients and providers that large electronic data-
bases might not offer.
Electronic databases such as pharmacy records and claim
databases can also have event capture issues. For instance, in the
United States, $4 generics being paid for with cash rather than
being paid out by their pharmacy beneﬁt manager as a usual and
customary price may be missed and therefore requires steps to
ensure that these gaps are addressed in the design. Studies thatdo not examine a patient’s prescription history before a prescrib-
ing event long enough will include PIMA patients in an IMA
measurement, likely overinﬂating the IMA estimate. This risk
diminishes as the preperiod gets longer until it is long enough to
cover all previous dispensing events. Determining the appropri-
ate length for an acute or chronic condition requires considering
supplemental factors presented later.
Conveying how well the core recommendations are met can
be challenging depending on the data source perspective.
A patient’s perspective should have the most prescribing and
dispensing event information, but the challenge is designing an
efﬁcient methodology to extract enough speciﬁc and detailed
information to make it practical. A pharmacist’s perspective may
have dispensing information, but how completely dispensing
events are captured, how prescribing events are captured, and
how therapy initiation was determined are challenges that must
be addressed. Research from a prescriber’s perspective should
have prescribing information, but it must describe how therapy
initiations are determined and dispensing events are captured. In
contrast, using electronic medical and claim records for a com-
bined perspective provides a broader capture of prescribing and
dispensing events information and leads to longer preperiods
and follow-up periods. Longer periods can be and were some-
times used to determine their appropriate lengths. This may not,
however, be an easy or practical option for many, and it faces
challenges associated with complete capture of dispensing
events. Regardless, any characteristics that may inﬂuence the
timing or capture of the prescribing and dispensing events should
be presented, as reﬂected in our Supplemental and Contextual
Recommendations sections.
Supplemental Recommendations
Supplemental recommendations are intended to address the
biases that may arise when measuring IMA. The ﬁrst recom-
mendation is to address perspective bias by ensuring the
comprehensiveness of information sources. IMA rates will be
artiﬁcially low if dispensing events occur outside of the perspec-
tive where they can be observed, such as when a patient has
more than one health insurance system or pays with cash. For
instance, in the United States, the extent to which a pharmacy
beneﬁt manager uses usual and customary pricing and deduc-
tible accumulation to increase the capture of $4 generics would
be valuable as context for assessing dispensing events in the
claim database. The second recommendation is to address
substitution bias, regardless of the source. Depending on the
type of medication and available information, researchers
should consider the possibility of substitution at the pharmacy,
which may not qualify as nonadherent behavior. This may
require a mechanism to identify ﬁlling within a therapeutic class
as potential adherent behavior or consideration of potential
over-the-counter substitution. Ideally, the focus should be
ensuring that a patient starts recommended pharmacotherapy
within a ﬁxed time window, even if the therapy requires revision
before receipt. Many studies do not report a procedure for
identifying successful ﬁlls of revised prescriptions, and therefore
may underestimate IMA.
In general, apparent nonadherent behavior based on available
dispensing event information should rule out any instance in
which a patient may actually be following instructions (e.g., pro
re nata [when necessary], substitutions, and censoring events).
One solution may involve a survey of nonadherent patients on
the reasons for their nonadherence. Because a survey may not be
feasible for every study, a review of the ﬁndings of similar studies
noted within this article can identify possible alternative explan-
ations for not ﬁlling a prescription. These explanations include
ﬁlling the prescription outside the normal health beneﬁt network,
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 9 0 – 6 9 9698substituting therapeutically equivalent medications, not wanting
any more medications, prescribing instructions to redeem a
prescription if another criterion is met (e.g., symptoms persist/
do not improve), or censoring due to emigration, uncaptured
physician/pharmacist events, hospitalization, or death. The
extent to which these can be addressed in the design should be
clearly noted, and if not, the potential impact of this limitation is
to be noted in the Discussion section. Overall, the researcher
should recognize the limitations of the data and that most may
not cover all physicians, pharmacists, or insurers.
Contextual Recommendations
Contextual recommendations are to include patient and non-
patient characteristics within the study design. This information
is crucial to understanding how observed IMA rates may apply or
be adjusted to speciﬁc populations, thus impacting generalizabil-
ity. Patient characteristics include health beliefs, insurance cov-
erage, barriers to obtaining care, illness severity, and other
medical or mental health comorbidities. These provide a better
understanding of the importance of medication to the patient,
and thus IMA. Investigating from the patient’s perspective
requires careful attention to the research design to elicit mean-
ingful information. Some of the nonpatient characteristics
include a description of the organization (e.g., health mainte-
nance organization and private family medicine clinic), phar-
macy formulary or medication co-payment policies, the
pharmacy itself (onsite vs. community, paper vs. electronic
prescription), and other nonpatient factors that can support
health policy, dissemination, generalizability, or further quality
improvement efforts.
Universal Recommendations
In addition to the IMA recommendation presented in Table 2,
there are a few universal recommendations that apply to most, if
not all, research. The objective of measuring IMA, research
signiﬁcance, and clinical implications should be presented clearly
and concisely. In the Methods section, researchers should deﬁne
the population, inclusion and exclusion criteria, and statistical
analyses to be performed. The Methods section should also
describe how the analyses will be performed and summarized,
and tables for presenting the analyses should include multiple
outcomes that present raw descriptive sample numbers, means,
conﬁdence intervals, and ranges, in addition to multivariable
models as pertinent. The outcomes and explanatory variables
should be clearly deﬁned, including the rationale for all statistical
tests undertaken—there should be a priori justiﬁcation for asso-
ciations. The Discussion section should tie results to stated
objectives explaining how they relate to past research and openly
acknowledge the strengths and limitations of the research
methods, such as the potential for overstating adherence rates
using medication possession ratios from administrative claim
databases and surveys being subject to patient recall.
We strongly believe that observing and incorporating these
recommendations into IMA research will foster better research,
enhance documentation of key ﬁndings, and enable a broader
audience to understand and incorporate relevant ﬁndings into
their clinical processes and patient outcomes improvement
efforts. Much work lies ahead to fully understand the role of
IMA in acute and chronic care, the health system, and provider
and patient factors that collectively inﬂuence the treatment
trajectory outlined here. Regardless of the perspective’s data
source limitation, IMA can be measured from any perspective if
the research includes core, supplemental, and contextual design
parameters.Acknowledgments
This article was developed as a collaborative effort of members of
the International Society of Pharmacoeconomics & Outcomes
Research (ISPOR) Medication Adherence and Compliance Special
Interest Group. We thank the more than 40 ISPOR members of the
Medication Adherence and Persistence Special Interest Group
reviewers for their helpful comments; their names can be found
on the ISPOR Web site. The ﬁndings were presented in a work-
shop at the ISPOR 19th Annual International Meeting held in
Montreal, Canada, in June 2014. All comments from the workshop
and the two manuscript reviews were addressed and incorpo-
rated as appropriate. Their feedback was very helpful in focusing
the manuscript and our thinking, and it contributed to the
consensus nature of this manuscript. We appreciate their time,
expertise, and insights.
Source of ﬁnancial support: None of the authors received
support for their participation in this Special Interest Group. All
authors volunteered their time for discussion, research, and
writing of this report. This research was supported in part by
the International Society for Pharmacoeconomics and Outcomes
Research, which contributed a staff liaison.
R E F E R E N C E S[1] Raoﬁ S, Schappert SM. Medication therapy in ambulatory medical care:
United States, 2003-04. Vital Health Stat 2006;163:1–40.
[2] Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to
medications: insights arising from studies on the unreliable link
between prescribed and actual drug dosing histories. Annu Rev
Pharmacol Toxicol 2012;52:275–301.
[3] Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to
study adherence to glaucoma medications: methodology and ﬁndings
of the Glaucoma Adherence and Persistency Study (GAPS). Invest
Ophthalmol Vis Sci 2007;48:5052–7.
[4] Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of
primary nonadherence after acute myocardial infarction. Circulation
2008;117:1028–36.
[5] Ko DT, Chiu M, Guo H, et al. Patterns of use of thienopyridine therapy
after percutaneous coronary interventions with drug-eluting stents and
bare-metal stents. Am Heart J 2009;158:592–8.
[6] Kulkarni AS, Balkrishnan R, Anderson RT, et al. Medication adherence
and associated outcomes in Medicare health maintenance
organization-enrolled older adults with Parkinson’s disease. Mov
Disord 2008;23:359–65.
[7] Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident
coronary heart disease associated with recently stopping the use of
beta-blockers. JAMA 1990;263:1653–7.
[8] Shah NR, Hirsch AG, Zacker C, et al. Factors associated with ﬁrst-ﬁll
adherence rates for diabetic medications: a cohort study. J Gen Intern
Med 2009;24:233–7.
[9] Shah NR, Hirsch AG, Zacker C, et al. Predictors of ﬁrst-ﬁll adherence for
patients with hypertension. Am J Hypertens 2009;22:392–6.
[10] Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate
therapy and fracture rates in osteoporotic women: relationship to
vertebral and nonvertebral fractures from 2 US claims databases. Mayo
Clin Proc 2006;81:9.
[11] Dragomir A, Cote R, White M, et al. Relationship between adherence
level to statins, clinical issues and health-care costs in real-life clinical
setting. Value Health 2010;13:87–94.
[12] Esposito D, Schone E, Williams T, et al. Prevalence of unclaimed
prescriptions at military pharmacies. J Manag Care Pharm 2008;14:12.
[13] Osterberg L, Blaschke T. Adherence to medication. N Engl J Med
2005;353:487–97.
[14] Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA.
Medication adherence leads to lower health care use and costs despite
increased drug spending. Health Aff (Millwood) 2011;30:91–9.
[15] Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of
medication adherence on hospitalization risk and healthcare cost. Med
Care 2005;43:521–30.
[16] Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing
and deﬁning adherence to medications. Br J Clin Pharmacol
2012;73:691–705.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 9 0 – 6 9 9 699[17] Cramer JA, Roy A, Burrell A, et al. Medication compliance and
persistence: terminology and deﬁnitions. Value Health 2008;11:
44–47.
[18] Zeber JE, Manias E, Williams AF, et al. A systematic literature review of
psychosocial and behavioral factors associated with initial medication
adherence: a report of the ISPOR Medication Adherence & Persistence
Special Interest Group. Value Health 2013;16:891–900.
[19] Raebel MA, Ellis JL, Carroll NM, et al. Characteristics of patients with
primary non-adherence to medications for hypertension, diabetes, and
lipid disorders. J Gen Intern Med 2011;27:8.
[20] Berger Z, Kimbrough W, Gillespie C, et al. Lower copay and oral
administration: predictors of ﬁrst-ﬁll adherence to new asthma
prescriptions. Am Health Drug Beneﬁts 2009;2:7.
[21] Cheetham TC, Niu F, Green K, et al. Primary nonadherence to statin
medications in a managed care organization. J Manag Care Pharm
2013;19:367–73.
[22] Derose SF, Green K, Marrett E, et al. Automated outreach to increase
primary adherence to cholesterol-lowering medications. JAMA Intern
Med 2013;173:38–43.
[23] Fernando TJ, Nguyen DD, Baraff LJ. Effect of electronically delivered
prescriptions on compliance and pharmacy wait time among
emergency department patients. Acad Emerg Med 2012;19:102–5.
[24] Fincham JE, Wertheimer AI. Initial noncompliance in the elderly.
J Geriatr Drug Ther 1986;1:11.
[25] Fischer MA, Stedman MR, Lii J, et al. Primary medication non-
adherence: analysis of 195,930 electronic prescriptions. J Gen Intern
Med 2010;25:284–90.
[26] Ginde AA, Von Harz BC, Turnbow D, Lewis LM. The effect of ED
prescription dispensing on patient compliance. Am J Emerg Med
2003;21:313–5.
[27] Gleason PP, Starner CI, Gunderson BW, et al. Association of prescription
abandonment with cost share for high-cost specialty pharmacy
medications. J Manag Care Pharm 2009;15:648–58.
[28] Kretzer K, Juarez DT, Davis J. Initial antihypertensive prescriptions,
switching patterns and adherence among insured patients in Hawai’i.
Hawaii Med J 2008;67:96–9: 111.
[29] McCaffrey DJ, Smith MC, Banahan MF, et al. Financial implications of
initial noncompliance in community pharmacies: an unclaimed
prescription audit pilot. J Res Pharm Econ 1998;9:25.
[30] McCaffrey DJ, Smith MC, Banahan MF, et al. The ﬁnancial implications
of initial noncompliance: an investigation of unclaimed prescriptions
in community pharmacies. J Res Pharm Econ 1995;6:16.
[31] Raebel MA, Carroll NM, Ellis JL, et al. Importance of including early
nonadherence in estimations of medication adherence. Ann
Pharmacother 2011;45:1053–60.
[32] Rosman SL, Dorfman D, Suglia SF, et al. Predictors of prescription ﬁlling
after visits to the pediatric emergency department. Pediatr Emerg Care
2012;28:22–5.
[33] Saks EK, Wiebe DJ, Cory LA, et al. Beliefs about medications as a
predictor of treatment adherence in women with urinary incontinence.
J Womens Health (Larchmt) 2012;21:440–6.
[34] Shin J, McCombs JS, Sanchez RJ, et al. Primary nonadherence to
medications in an integrated healthcare setting. Am J Manag Care
2012;18:426–34.
[35] Shrank WH, Choudhry NK, Fischer MA, et al. The epidemiology of
prescriptions abandoned at the pharmacy. Ann Intern Med
2010;153:633–40.
[36] Solomon MD, Goldman DP, Joyce GF, Escarce JJ. Cost sharing and the
initiation of drug therapy for the chronically ill. Arch Intern Med
2009;169:740–8: discussion 748–9.
[37] Streeter SB, Schwartzberg L, Husain N, Johnsrud M. Patient and plan
characteristics affecting abandonment of oral oncolytic prescriptions.
J Oncol Pract 2011;7(3, Suppl.):46s–51s.
[38] Suffoletto B, Calabria J, Ross A, et al. A mobile phone text message
program to measure oral antibiotic use and provide feedback on
adherence to patients discharged from the emergency department.
Acad Emerg Med 2012;19:949–58.
[39] Trinacty CM, Adams AS, Soumerai SB, et al. Racial differences in long-
term adherence to oral antidiabetic drug therapy: a longitudinal cohort
study. BMC. Health Serv Res 2009;9:24.
[40] Williams LK, Joseph CL, Peterson EL, et al. Patients with asthma who do
not ﬁll their inhaled corticosteroids: a study of primary nonadherence.
J Allergy Clin Immunol 2007;120:1153–9.[41] Wroth TH, Pathman DE. Primary medication adherence in a rural
population: the role of the patient-physician relationship and
satisfaction with care. J Am Board Fam Med 2006;19:478–86.
[42] Karter AJ, Parker MM, Moffet HH, et al. New prescription medication
gaps: a comprehensive measure of adherence to new prescriptions.
Health Serv Res 2009;44:1640–61.
[43] Kessler RC, Cantrell CR, Berglund P, Sokol MC. The effects of
copayments on medication adherence during the ﬁrst two years
of prescription drug treatment. J Occup Environ Med 2007;49:
597–609.
[44] Liberman JN, Hutchins DS, Popiel RG, et al. Determinants of primary
non-adherence to asthma control and dsylipidemia pharmacotherapy.
Am J Pharm Ben 2010;61:3.
[45] Yood RA, Mazor KM, Andrade SE, et al. Patient decision to initiate
therapy for osteoporosis: the inﬂuence of knowledge and beliefs. J Gen
Intern Med 2008;23:1815–21.
[46] Arslan LS, Semin S. Attitudes and practices of primary healthcare
center patients about drug use in Turkey. Pat Educ Couns
2006;62:250–9.
[47] Beardon PH, McGilchrist MM, McKendrick AD, et al. Primary non-
compliance with prescribed medication in primary care. BMJ
1993;307:846–8.
[48] Ekedahl A, Mansson N. Unclaimed prescriptions after automated
prescription transmittals to pharmacies. Pharm World Sci
2004;26:26–31.
[49] Freeman CP, Guly HR. Do accident and emergency patients collect their
prescribed medication? Arch Emerg Med 1985;2:41–3.
[50] Hansen DG, Vach W, Rosholm JU, et al. Early discontinuation of
antidepressants in general practice: association with patient and
prescriber characteristics. Fam Pract 2004;21:623–9.
[51] Jones I, Britten N. Why do some patients not cash their prescriptions?
Br J Gen Pract 1998;48:903–5.
[52] Matsui D, Joubert GI, Dykxhoorn S, Rieder MJ. Compliance with
prescription ﬁlling in the pediatric emergency department. Arch
Pediatr Adolesc Med 2000;154:195–8.
[53] Menckeberg TT, Bouvy ML, Bracke M, et al. Patients’ understanding of
the reasons for starting and discontinuing inhaled corticosteroids. Br J
Clin Pharmacol 2008;66:255–60.
[54] Skutnik S, Katsanis LP. The impact of initial noncompliance in
Canadian retail pharmacies: a descriptive examination. J Pharm
Marketing Manag 1997;11:20.
[55] Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are
never redeemed: primary nonadherence in an outpatient clinic. J Am
Acad Dermatol 2008;59:27–33.
[56] Wamala S, Merlo J, Bostrom G, et al. Socioeconomic disadvantage and
primary non-adherence with medication in Sweden. Int J Qual Health
Care 2007;19:134–40.
[57] Watts RW, McLennan G, Bassham I, el-Saadi O. Do patients with
asthma ﬁll their prescriptions? A primary compliance study. Aust Fam
Phys 1997;26(Suppl. 1):S4–6.
[58] Wright H, Forbes D, Graham H. Primary compliance with medication
prescribed for paediatric patients discharged from a regional hospital.
J Paediatr Child Health 2003;39:611–2.
[59] van Geffen EC, Gardarsdottir H, van Hulten R, et al. Initiation of
antidepressant therapy: do patients follow the GP’s prescription? Br J
Gen Pract 2009;59:81–7.
[60] Fischer MA, Choudhry NK, Brill G, et al. Trouble getting started: predictors
of primary medication nonadherence. Am J Med 2011;124(1081):e9–22.
[61] Hugtenburg JG, Blom AT, Kisoensingh SU. Initial phase of chronic
medication use: patients’ reasons for discontinuation. Br J Clin
Pharmacol 2006;61:352–4.
[62] Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment
predictors of statin adherence. Med Care 2010;48:196–202.
[63] Peuskens J, Olivares JM, Pecenak J, et al. Treatment retention with
risperidone long-acting injection: 24-month results from the Electronic
Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
Curr Med Res Opin 2010;26:501–9.
[64] Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence
across 6 chronic medication classes. J Manag Care Pharm 2009;15:728–40.
[65] Alliance PQ. PQA membership endorses two new performance
measures. Available from: http://www.pqaalliance.org/images/
uploads/ﬁles/1-PQA%20Membership%20Endorses%20Two%20New%
20Performance%20Measures-%20F1.pdf. [Accessed March 1, 2013].
